Researchers isolated a molecule that may be under-produced in the guts of patients
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. As reported today in Nature,progression of an ALS-like disease was slowed after the mice received certain strains of gut microbes or substances known to be secreted by these microbes. Preliminary results suggest that the findings on the regulatory function of the microbiome may be applicable to human patients with ALS.
“Our long-standing scientific and medical goal is to elucidate the impact of the microbiome on human health and disease, with the brain being a fascinating new frontier,” says Prof. Eran Elinav of the Immunology Department. His team performed the study together with that of Prof. Eran Segal of the Computer Science and Applied Mathematics Department. Segal elaborates: “Given increasing evidence that microbiome affects brain function and disease, we wanted to study its potential role in ALS.” The study was led by postdoctoral fellows Drs. Eran Blacher and Stavros Bashiardes, and by staff scientist Dr. Hagit Shapiro, all in the Elinav lab. They collaborated with Dr. Daphna Rothschild, a postdoctoral fellow in Eran Segal’s lab, and Dr. Marc Gotkine, Head of the Motor Neuron Disease Clinic at Hadassah Medical Center, as well as with other scientists from Weizmann and elsewhere.
The scientists started out demonstrating in a series of experiments that the symptoms of an ALS-like disease in transgenic mice worsened after these mice were given broad-spectrum antibiotics to wipe out a substantial portion of their microbiome. In addition, the scientists found that growing these ALS-prone mice in germ-free conditions (in which, by definition, mice carry no microbiome of their own), is exceedingly difficult, as these mice had a hard time surviving in the sterile environment. Together, these results hinted at a potential link between alterations in the microbiome and accelerated disease progression in mice that were genetically susceptible to ALS.
Next, using advanced computational methods, the scientists characterized the composition and function of the microbiome in the ALS-prone mice, comparing them to regular mice. They identified 11 microbial strains that became altered in ALS-prone mice as the disease progressed or even before the mice developed overt ALS symptoms. When the scientists isolated these microbial strains and gave them one by one – in the form of probiotic-like supplements – to ALS-prone mice following antibiotic treatment, some of these strains had a clear negative impact on the ALS-like disease. But one strain, Akkermansia muciniphila, significantly slowed disease progression in the mice and prolonged their survival.
To reveal the mechanism by which Akkermansia may be producing its effect, the scientists examined thousands of small molecules secreted by the gut microbes. They zeroed in on one molecule called nicotinamide (NAM): Its levels in the blood and in the cerebrospinal fluid of ALS-prone mice were reduced following antibiotic treatment and increased after these mice were supplemented with Akkermansia, which was able to secrete this molecule. To confirm that NAM was indeed a microbiome-secreted molecule that could hinder the course of ALS, the scientists continuously infused the ALS-prone mice with NAM. The clinical condition of these mice improved significantly. A detailed study of gene expression in their brains suggested that NAM improved the functioning of their motor neurons.
One strain significantly slowed disease progression in the mice and prolonged their survival
Finally, the researchers examined the microbiome and metabolite profiles of 37 human ALS patients and compared them to those of family members sharing the same household. A detailed genomic analysis suggested that the gut microbiomes of ALS patients were distinct in composition and functional features from those of healthy controls. In particular, numerous microbial genes involved in the synthesis of NAM were significantly suppressed in ALS patients. An analysis of thousands of small molecules in the blood also revealed a distinct pattern in ALS patients as compared to controls. Here too, many of the intermediary molecules involved in the NAM synthesis were altered in the blood of ALS patients. When the researchers tested the levels of NAM itself, they found these to be significantly reduced in both the blood and the brain of 60 human ALS patients as compared to controls. Moreover, there was a correlation between reduced NAM levels and the degree of muscle weakness in the patients.
“These findings are only a first step towards achieving a comprehensive understanding of the potential impact of the microbiome on ALS,” Elinav says, “but they suggest that in the future, various means of altering the microbiome may be harnessed for developing new therapeutic options for ALS.”
Learn more: Gut Microbes May Affect the Course of ALS
The Latest on: Amyotrophic lateral sclerosis
via Google News
The Latest on: Amyotrophic lateral sclerosis
- Anelixis Therapeutics Announces a Financing Led by BVF Partners L.P. to Fund Phase 2 Development of AT-1501on November 18, 2019 at 4:13 pm
Financing to Support Clinical Development of AT-1501 in Amyotrophic Lateral Sclerosis (ALS), Transplant Rejection and Autoimmune Diseases Company Also Announces Successful Completion of Phase 1 Study ...
- ALS Prevalent Among Young Veterans Deployed in Post-9/11 U.S. Wars, Study Showson November 18, 2019 at 4:00 am
Amyotrophic lateral sclerosis (ALS) is highly prevalent among young U.S. war veterans deployed post-9/11, particularly Air Force personnel, tactical operation officers, and health care workers, a ...
- Neurodegenerative diseases and neuroinflammation: Getting the balance righton November 17, 2019 at 7:49 pm
Chronic neuroinflammation, a feature common to neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis, might be responsive to therapeutic ...
- Francis Michael Gattion November 16, 2019 at 10:22 pm
Francis Michael Gatti was born in Philadelphia on June 23, 1956. He was diagnosed with Amyotrophic Lateral Sclerosis ALS or Lou Gehrig's decease in May of 2016 and died on November 12, 2019.
- Late coach Bill Walsh's No. 16 all over Holy Spirit football gameon November 15, 2019 at 3:45 pm
No excuses.” Walsh lived like he coached. The former Spartans football coach and administrator died at his Galloway Township home Friday morning after a battle with amyotrophic lateral sclerosis, ...
- Former Holy Spirit football coach Bill Walsh dies after long battle with ALSon November 15, 2019 at 1:39 pm
A 1985 graduate and head football coach from 2003-2007, Walsh died after battling Lou Gehrig's disease - amyotrophic lateral sclerosis, known more as ALS. He was diagnosed in early 2016. "The ...
- Bill would allow individuals with sickle cell disease to use medical marijuanaon November 15, 2019 at 9:26 am
Those conditions include cancer, epilepsy, glaucoma, testing positive for HIV or AIDS, Posttraumatic stress disorder (PTSD), amyotrophic lateral sclerosis, Crohn’s disease, Parkinson’s disease and ...
- Aquestive Licenses ALS Therapy Riluzole Oral Film to Zambon in the European Unionon November 15, 2019 at 4:14 am
Aquestive Therapeutics has granted a development and commercialization license to Zambon Pharma for its investigational oral film formulation of riluzole as a treatment for amyotrophic lateral ...
- ProMIS Neurosciences Announces Third Quarter 2019 Resultson November 14, 2019 at 6:07 am
"In the third quarter of this year, we continued to generate further data supporting our antibody candidates for Parkinson's disease (targeting toxic forms of alpha-synuclein), amyotrophic lateral ...
- BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Societyon November 14, 2019 at 3:00 am
BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to ...
via Bing News